Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of BIBR 277 Tablet vs Capsule in Healthy Males
NCT02262559Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2002
- Primary completion
- Aug 2002
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of telmisartan in hypertension (HTN) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum observed concentration of Telmisartan in plasma up to 72 hours and Area under the concentration-time curve from zero to 72hr. Started Jul 2002; status: completed.
02
Drugs
telmisartan
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT02262559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02262559.